Royalty Pharma Net Income Over Time
| RPRX Stock | USD 44.05 0.60 1.34% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Royalty Pharma Performance and Royalty Pharma Correlation. Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Royalty Pharma. Anticipated expansion of Royalty directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Royalty Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.45) | Dividend Share 0.87 | Earnings Share 1.75 | Revenue Per Share | Quarterly Revenue Growth 0.079 |
Understanding Royalty Pharma Plc requires distinguishing between market price and book value, where the latter reflects Royalty's accounting equity. The concept of intrinsic value - what Royalty Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Royalty Pharma's price substantially above or below its fundamental value.
It's important to distinguish between Royalty Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Royalty Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Royalty Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Royalty Pharma Plc and related stocks such as Genmab AS, United Therapeutics, and Incyte Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GMAB | (479.3 M) | (596.4 M) | (487.1 M) | 112.4 M | 301.3 M | 763.5 M | 1.2 B | 1.1 B | 1.5 B | 2.2 B | 4.8 B | 3 B | 5.5 B | 4.4 B | 7.8 B | 9 B | 9.5 B |
| UTHR | (12.8 M) | 217.9 M | 304.4 M | 174.6 M | 340.1 M | 651.6 M | 713.7 M | 417.9 M | 589.2 M | (104.5 M) | 514.8 M | 475.8 M | 727.3 M | 984.8 M | 1.2 B | 1.4 B | 1.4 B |
| INCY | (4.9 M) | (186.5 M) | (44.3 M) | (83.1 M) | (48.5 M) | 6.5 M | 104.2 M | (313.1 M) | 109.5 M | 446.9 M | (295.7 M) | 948.6 M | 340.7 M | 597.6 M | 32.6 M | 37.5 M | 39.4 M |
| FMS | 82 M | 826.4 M | 897.4 M | 803.8 M | 859.4 M | 941.2 M | 1.2 B | 1.3 B | 2 B | 1.2 B | 1.2 B | 969.3 M | 673.4 M | 499 M | 537.9 M | 618.6 M | 708.2 M |
| SMMT | (42 K) | (4.2 M) | (6.7 M) | (10.1 M) | (17.1 M) | (24.3 M) | (21.4 M) | (28.5 M) | 9.9 M | 5 M | (52.7 M) | (86.1 M) | (78.8 M) | (614.9 M) | (221.3 M) | (199.2 M) | (189.2 M) |
| SNN | 68.4 M | 582 M | 729 M | 556 M | 501 M | 410 M | 784 M | 767 M | 663 M | 600 M | 448 M | 524 M | 223 M | 263 M | 412 M | 473.8 M | 371.1 M |
| ROIV | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | (1 B) | 1.2 B | (809.2 M) | (845.3 M) | (1 B) | 4.3 B | (172 M) | (197.8 M) | (187.9 M) |
| HOLX | 1.4 M | (73.6 M) | (1.2 B) | 17.3 M | 131.6 M | 330.8 M | 755.5 M | (111.3 M) | (40.2 M) | 1.1 B | 1.9 B | 1.3 B | 456 M | 789.5 M | 565.7 M | 650.6 M | 683.1 M |
| THC | 63 M | 82 M | 152 M | (134 M) | 12 M | (140 M) | (192 M) | (704 M) | 104 M | (215 M) | 399 M | 914 M | 411 M | 611 M | 3.2 B | 3.7 B | 3.9 B |
| EXEL | (15.7 M) | 75.7 M | (147.6 M) | (244.8 M) | (268.5 M) | (169.7 M) | (70.2 M) | 154.2 M | 690.1 M | 321 M | 111.8 M | 231.1 M | 182.3 M | 207.8 M | 521.3 M | 599.5 M | 629.4 M |
Royalty Pharma Plc and related stocks such as Genmab AS, United Therapeutics, and Incyte Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Royalty Pharma Plc financial statement analysis. It represents the amount of money remaining after all of Royalty Pharma Plc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Royalty Pharma Plc | RPRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 110 East 59th |
| Exchange | NASDAQ Exchange |
USD 44.05
Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.